Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 in obesity/overweight
NCT06728124Phase 3Active, not recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing GZR18 with Placebo (2 arms). Primary endpoint: Percent change in weight from baseline at 48 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
bofanglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06728124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06728124.